- Home
- SVRA vs RGNX Comparison
SVRA vs RGNX Comparison
Compare SVRA & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- RGNX
- Stock Information
- Founded
- SVRA 2007
- RGNX 2008
- Country
- SVRA United States
- RGNX United States
- Employees
- SVRA N/A
- RGNX N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SVRA Health Care
- RGNX Health Care
- Exchange
- SVRA Nasdaq
- RGNX Nasdaq
- Market Cap
- SVRA 473.6M
- RGNX 424.8M
- IPO Year
- SVRA N/A
- RGNX 2015
- Fundamental
- Price
- SVRA $3.04
- RGNX $8.82
- Analyst Decision
- SVRA Buy
- RGNX Strong Buy
- Analyst Count
- SVRA 7
- RGNX 8
- Target Price
- SVRA $5.57
- RGNX $28.50
- AVG Volume (30 Days)
- SVRA 1.1M
- RGNX 692.5K
- Earning Date
- SVRA 08-13-2025
- RGNX 08-07-2025
- Dividend Yield
- SVRA N/A
- RGNX N/A
- EPS Growth
- SVRA N/A
- RGNX N/A
- EPS
- SVRA N/A
- RGNX N/A
- Revenue
- SVRA N/A
- RGNX $155,782,000.00
- Revenue This Year
- SVRA N/A
- RGNX $327.08
- Revenue Next Year
- SVRA N/A
- RGNX N/A
- P/E Ratio
- SVRA N/A
- RGNX N/A
- Revenue Growth
- SVRA N/A
- RGNX 74.95
- 52 Week Low
- SVRA $1.89
- RGNX $5.04
- 52 Week High
- SVRA $4.70
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- SVRA 69.39
- RGNX 54.02
- Support Level
- SVRA $2.43
- RGNX $7.35
- Resistance Level
- SVRA $2.77
- RGNX $9.25
- Average True Range (ATR)
- SVRA 0.20
- RGNX 0.54
- MACD
- SVRA 0.04
- RGNX 0.08
- Stochastic Oscillator
- SVRA 71.76
- RGNX 74.62
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.